Health And Pharma

AACR 2026 Data Show Abbott’s Multi-Biomarker MCED Approach Improves Early Cancer Detection

At AACR 2026, Abbott presented data on Cancerguard, a multi-biomarker blood-based MCED test that combines methylation and ...
Health And Pharma

FDA Grants Breakthrough Designation to First Urine-Based Multi-Cancer Early Detection Test

TOBY’s urine-based MCED test received FDA Breakthrough Device Designation. This is the first urine-based MCED platform ...
Health And Pharma

Zenocutuzumab Gains NCCN Support as FDA Review Advances in Cholangiocarcinoma

Partner Therapeutics has submitted a supplemental Biologics License Application to the U.S. FDA for BIZENGRI, ...
Health And Pharma

Illumina and D3b Launch 100 K Genome Effort to Advance Pediatric Cancer and Rare Disease Research

Illumina and D3b, have announced a new data partnership aimed at accelerating research in pediatric cancer and rare disease, ...
Health And Pharma

AI-Driven Nodule Detection Helps Sarasota Memorial Reach 75% Early-Stage Lung Cancer Diagnosis Rate

Sarasota Memorial reported that 75% of lung cancers diagnosed through its early detection program were found at Stage I or II ...
Health And Pharma

FDA Grants Priority Review to Ifinatamab Deruxtecan in Pretreated ES-SC Lung Cancer

FDA has accepted and granted Priority Review to the biologics license application for ifinatamab deruxtecan in adults with ...
healthandpharma

Neladalkib Reaches FDA Review for TKI-Pretreated ALK-Positive Non-Small Cell Lung Cancer

Neladalkib has been submitted for FDA review in TKI pre-treated advanced ALK-positive NSCLC, based on data from the global ALKOVE-1 Phase 1/2 trial. The brain-penetrant, ALK-selective inhibitor showed ...